Clinical TrialApr 27, 2026, 07:02 AM
FULC Pociredir Positive Clinical Data; Registration Trial H2 2026
AI Summary
Fulcrum Therapeutics reported positive clinical data for pociredir in sickle cell disease, showing robust fetal hemoglobin induction and improvements in hemolysis and anemia markers, with encouraging trends in VOC reduction. The company plans to initiate a potential registration-enabling trial in the second half of 2026 and has dosed the first patient in a long-term safety trial. Additionally, Josh Lehrer, M.D., was appointed to the Board, and CFO Alan Musso announced his retirement. Fulcrum ended Q1 2026 with $333.3 million in cash, extending its cash runway into 2029.
Key Highlights
- Positive clinical data for pociredir in SCD, demonstrating robust and rapid HbF induction.
- Fulcrum plans to initiate a potential registration-enabling trial in H2 2026.
- First patient dosed in an open-label, long-term dosing trial for pociredir.
- Josh Lehrer, M.D., appointed to the Board of Directors.
- CFO Alan Musso plans to retire later this year.
- Q1 2026 cash, cash equivalents, and marketable securities totaled $333.3 million.
- Cash runway is projected to extend into 2029.
- Q1 2026 net loss was $18.9 million.